iKang to Form an Investment Fund with AVIC Trust Co., Ltd. and Make A Re-Financing Arrangement
Jan 03, 2018 11:00 am UTC| Business
BEIJING, Jan. 03, 2018 -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced that it will form...
Incorta Expands Executive Roster with Two New Hires
Jan 03, 2018 11:00 am UTC| Business
SAN MATEO, Calif., Jan. 03, 2018 -- Incorta, the enterprise analytics platform that bypasses data modeling to deliver real-time insights straight from operational data, today announced two new executive hires: Karl...
Eagle Bancorp Announces Earnings Call On January 18, 2018
Jan 03, 2018 11:00 am UTC| Business
BETHESDA, Md., Jan. 03, 2018 -- Eagle Bancorp, Inc., (the “Company”) (NASDAQ:EGBN), the parent company of EagleBank, today announced that it will host a teleconference call for the financial community on January 18,...
Jan 03, 2018 11:00 am UTC| Business
DALLAS, Jan. 03, 2018 -- In just one year, student reading success at Rapides Parish Schools has improved dramatically after the implementation of a new teacher professional development course of study, Voyager Sopris...
Jan 03, 2018 10:54 am UTC| Business
Albany, NY, Jan. 03, 2018 -- Prominent names in the global methanol market include Celanese Corporation, SABIC, Mitsui Chemicals Inc., Methanex Corporation, BASF SE, and Mitsubishi Chemical Holdings Corporation. Leading...
Global Synthetic Fibers Market to Gain Traction from Rising Furnishing Needs in Houses, States TMR
Jan 03, 2018 10:37 am UTC| Business
Albany, NY, Jan. 03, 2018 -- The growing usage of synthetic fibers across a wide array of domains, especially the fashion industry, has been upscaling the market for these fibers. The presence of a large number of...
Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
Jan 03, 2018 10:30 am UTC| Business
MELBOURNE, Australia, Jan. 03, 2018 -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, has commenced a Phase 1b/2a trial evaluating...